Treatment with deferasirox (Exjade®) effectively decreases iron burden in patients with thalassaemia intermedia: Results of a pilot study: Correspondence

British Journal of Haematology

Volumn 148, Issue 2, 2010, Pages 332-334

  Voskaridou, Ersi ^a   Plata, Eleni ^a   Douskou, Maroussa ^b   Papadakis, Manousos ^a   Delaki, Eleni Evangelia ^a   Christoulas, Dimitrios ^c   Terpos, Evangelos ^c  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b BIOIATRIKI HEALTHCARE GROUP   (Greece)

^c 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

Iron chelation therapy; Iron overload; Magnetic resonance imaging; T2; Thalassaemia intermedia

Indexed keywords

CYSTATIN C; DEFERASIROX;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFORMED CONSENT; IRON ABSORPTION; IRON CHELATION; IRON OVERLOAD; LETTER; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; PULMONARY HYPERTENSION; SIDE EFFECT; THALASSEMIA; THALASSEMIA INTERMEDIA; TREATMENT DURATION;

ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; FEMALE; FERRITINS; HEART; HUMANS; IRON CHELATING AGENTS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 72649101965     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07930.x     Document Type: Letter

References (10)

1. Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., McLaren, C.E., Young, N.S., Tucker, E.E., Allen, C.J., Farrell, D.E. Harris, J.W. (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. New England Journal of Medicine, 331, 567 573.
2. Cappellini, M.D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J., Capra, M., Galanello, R., Fattoum, S., Drelichman, G., Magnano, C., Verissimo, M., Athanassiou-Metaxa, M., Giardina, B., Kourakli-Symeonidis, A., Janka-Schaub, G., Coates, T., Vermylen, C., Olivieri, N., Thuret, I., Opitz, H., Ressayre-Djaffer, C., Marks, P. Alberti, D. (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood, 107, 3455 3462.
3. Cossu, P., Toccafondi, C., Vardeu, F., Sanna, G., Frau, F., Lobrano, R., Cornacchia, G., Nucaro, A., Bertolino, F., Loi, A., De Virgiliis, S. Cao, A. (1981) Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. European Journal of Pediatrics, 137, 267 271.
4. Jensen, P.D. (2004) Evaluation of iron overload. British Journal of Haematology, 124, 697 711.
5. Olivieri, N.F., Koren, G., Matsui, D., Liu, P.P., Blendis, L., Cameron, R., McClelland, R.A. Templeton, D.M. (1992) Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood, 79, 2741 2748.
6. Origa, R., Barella, S., Argiolas, G.M., Bina, P., Agus, A. Galanello, R. (2008) No evidence of cardiac iron in 20 never or minimally transfused patients with thalassemia intermedia. Haematologica, 93, 1095 1096.
7. Pakbaz, Z., Fischer, R., Fung, E., Nielsen, P., Harmatz, P. Vichinsky, E. (2007) Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatric Blood Cancer, 49, 329 332.
8. Thalassaemia International Federation (2008) Guidelines for the Clinical Management of Thalassaemia, 2nd Revised edn. TIF edition, Nicosia, Cyprus. Available at: http://www.thalassaemia.org.cy/pdf/Guidelines-2nd-revised-edition- EN.pdf.
9. Vichinsky, E. (2008) Clinical application of deferasirox: practical patient management. American Journal of Hematology, 83, 398 402.
10. Wood, J.C., Enriquez, C., Ghugre, N., Tyzka, J.M., Carson, S., Nelson, M.D. Coates, T.D. (2005) MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood, 106, 1460 1465.